Quotes 5-day view Delayed Nasdaq
09/16/2021
09/17/2021
09/20/2021
09/21/2021
09/22/2021
Date
653.18(c)
651.88(c)
640.89(c)
646.95(c)
647.06 Last
540 043
762 045
666 652
440 841
499 236 Volume
+0.18% -0.20% -1.69% +0.95% +0.02% Change
Estimated financial data (e) (USD)
Sales 2021
13 864 M - -
Net income 2021
6 822 M - -
Net cash position 2021
6 794 M - -
P/E ratio 2021
10,3x
Yield 2021
-
Sales 2022
12 209 M - -
Net income 2022
4 564 M - -
Net cash position 2022
9 282 M - -
P/E ratio 2022
15,0x
Yield 2022
-
Capitalization
67 262 M 67 262 M -
EV / Sales 2021
4,36x
EV / Sales 2022
4,75x
Nbr of Employees
9 635
Free-Float
82,0%
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,...
Ratings of Regeneron Pharmaceuticals
All news about REGENERON PHARMACEUTICALS
10:08a REGENERON PHARMACEUTICALS : New dupixent (dupilumab) data in patients as young as six year..AQ
09:42a WALL STREET STOCK EXCHANGE : Fed verdict is imminent06:34a ANALYST RECOMMENDATIONS : Blackstone, Burberry, FedEx, Hershey, Micron Technology...09/21 EU signs joint procurement deal for Eli Lilly COVID-19 treatment RE
09/21 REGENERON PHARMACEUTICALS : BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to..MT
09/21 REGENERON PHARMACEUTICALS : New Dupixent® (dupilumab) Data in Patients as Young as Six Yea..PR
09/20 REGENERON PHARMACEUTICALS : Esmo late-breaking data show libtayo (cemiplimab) and chemothe..AQ
09/20 SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..AQ
09/20 Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar DJ
09/20 SANOFI : Regeneron, Sanofi Say Lung Cancer Drug Libtayo Improves Overall Patient Survival ..MT
09/20 SANOFI : Regeneron's Libtayo Combo Extends Lung Cancer Patients' Lives In Phase 3 StudyMT
09/17 INSIDER SELL : Regeneron PharmaceuticalsMT
09/16 REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K)AQ
09/16 Regeneron Pharmaceuticals, Inc. Enters into Supply Agreement with Army Contracting Comm.. CI
09/15 AFTER HOURS WATCH LIST SCORECARD : Yumc, regn, lyv,MT
News in other languages on REGENERON PHARMACEUTICALS
Analyst Recommendations on REGENERON PHARMACEUTICALS
REGENERON PHARMACEUTICALS - 09/21
Technically solid
BUY
Regeneron Pharmaceuticals : sees uptick in COVID-19 therapy use as cases rise
Chart REGENERON PHARMACEUTICALS
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends REGENERON PHARMACEUTICALS
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
646,95 $
Average target price
681,41 $
Spread / Average Target
5,33%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
